Last reviewed · How we verify
ASTX727 Dose Confirmation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ASTX727 Dose Confirmation (ASTX727 Dose Confirmation) — Astex Pharmaceuticals, Inc.. Combines decitabine (DNA hypomethylating agent) with cedazuridine (cytidine deaminase inhibitor) to enable oral administration and improve bioavailability.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ASTX727 Dose Confirmation TARGET | ASTX727 Dose Confirmation | Astex Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ASTX727 Dose Confirmation CI watch — RSS
- ASTX727 Dose Confirmation CI watch — Atom
- ASTX727 Dose Confirmation CI watch — JSON
- ASTX727 Dose Confirmation alone — RSS
Cite this brief
Drug Landscape (2026). ASTX727 Dose Confirmation — Competitive Intelligence Brief. https://druglandscape.com/ci/astx727-dose-confirmation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing